BioPorto A/S Announces Intention to Initiate a Rights Issue with Pre-emptive Subscription Rights for Existing Shareholders

Plus updates on the status of The NGAL Test clinical trials for De Novo application to the U.S. FDA; 2021 financial estimate and guidance for 2022

March 7, 2022

Pipeline Update on gRAD Tests

The generic Rapid Assay Device (gRAD) technology is being used by Rigshospitalet, Copenhagen, to investigate the potential for thrombomodulin blood levels to be used as a marker in patients with sepsis and in a feasibility study to detect SARS-CoV-2e

December 31, 2021

New Composition of the Management Board of BioPorto A/S

New CEO Anthony Pare and CFO Neil A. Goldman appointed; Peter Mørch Eriksen to join as a member of the Board of Directors

November 19, 2021

BioPorto Successfully Completes Interim Analysis of Data from Pivotal Study of NGAL in Pediatrics with Encouraging Results

Includes data collected from six different leading US children’s hospitals over a twelve-month period.

August 31, 2021

BioPorto Initiates Patient Enrollment for US Pediatric Study of The NGAL Test™

First patients enrolled at Cincinnati Children’s Hospital, a leading US center for critical care nephrology.

June 23, 2020

Danish Team of Researchers to Test Treatment of Critically Ill Patients Suffering from COVID-19

The Innovation Fund Denmark has awarded DKK 3 million to test if the drug Iloprost can improve survival rates in SARS-Co-V2 infected patients in need of respiratory treatment.

May 14, 2020

BioPorto and the University of Southern Denmark in collaboration to fast track development of test to detect COVID-19 in less than 10 minutes

The inexpensive, reliable and effective point-of-care test is expected to be available in the 2nd half of 2020.

April 1, 2020